Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

Slides:



Advertisements
Similar presentations
1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.
Advertisements

ALLHAT New Research Opportunities.
11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT JB Kostis, B Davis, L Simpson, H Black, W Cushman, P Einhorn, M.
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute The Antihypertensive and Lipid-Lowering.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.
Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.
1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
1 Setting the Record Straight ALLHAT. 2 Major ALLHAT Findings CHD risk not improved for any of the 3 newer agents compared with chlorthalidone Total mortality.
Blood Pressure Control By Randomized Drug Group In ALLHAT William C. Cushman, Charles E. Ford, Paula T. Einhorn, Jackson T. Wright, Jr., Richard A. Preston,
Blood Pressure Control in Hispanics in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Karen L. Margolis, Linda.
Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid- lowering Treatment to Prevent Heart.
Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,
1 ATRIAL FIBRILLATION AT BASELINE AND DURING FOLLOW-UP in The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial November 9, 2003.
1 U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Major Outcomes in High Risk Hypertensive.
1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.
1 Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial ALLHAT Davis.
Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):
1 Can One Evaluate An Outcomes Claim Based On An Active Controlled Study? Pfizer Response Cardiovascular and Renal Drugs Advisory Committee Rockville,
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
1 Review of the Design and Initial Findings for Pre-specified Outcomes and Subgroups Paul K. Whelton, M.D., M.Sc. Loyola University Medical Center Maywood,
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
10/11/ Fasting Glucose Levels & Incident Diabetes Mellitus in Older Non-Diabetic Adults Randomized to Three Different Classes of Antihypertensive.
Heart Failure (HF) Findings: Are They Real? Stanley S. Franklin, MD, FACP, FACC Clinical Professor of Medicine University of California at Irvine Associate.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute ALLHAT Major Outcomes in Moderately.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
4S: Scandinavian Simvastatin Survival Study
Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
What should the Systolic BP treatment goal be in patients with CKD?
Health and Human Services National Heart, Lung, and Blood Institute
Vanguard Phase Results for the Blood Pressure Component
ALLHAT ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
The Anglo Scandinavian Cardiac Outcomes Trial
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
ALLHAT Do the SBP differences between the lisinopril and chlorthalidone arms explain the differences in CVD outcomes?
The Hypertension in the Very Elderly Trial (HYVET)
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Health and Human Services National Heart, Lung, and Blood Institute
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Post-Heart Failure Mortality
The following slides highlight a report by Dr
Presentation transcript:

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs

Objective and Rationale To compare major outcomes for pts remaining on blinded monotherapy. Aim: to remove effects of step-up drugs that may have differed in effectiveness depending on Step 1 class. Main limitation: departure from intent-to- treat introduces possible confounding. ALLHAT

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Practice-based, randomized trial conducted at 623 N. American & Caribbean sites Antihypertensive component –42,418 high-risk hypertensives >= 55 years –whether newer agents reduce incidence of CHD compared to a diuretic –double-blind –no placebo ALLHAT

Major Outcomes Nonfatal MI/CHD death (primary) All-cause mortality Stroke Combined CHD – nonfatal MI, CHD death, coronary revascularization, hospitalized angina Combined CVD – combined CHD, stroke, lower extremity revascularization, treated angina, fatal / hospitalized / treated heart failure (HF), hospitalized or outpatient PAD ALLHAT

42,418 high-risk hypertensive patients 90% previously treated 10% untreated STEP 1 AGENTS Chlorthalidone mg Amlodipine mg Lisinopril mg Doxazosin 1-8 mg N=15,255 N=9,048 N=9,054 N=9,061 STEP 2 AND 3 AGENTS (5 years) Atenolol 28.0% Clonidine 10.6% Reserpine 4.3% Hydralazine 10.9% Hypertension Trial ALLHAT

Year 1 Cohort Criteria On only Step 1 (blinded) therapy at the year 1 (first annual) follow-up visit Have not had a cardiovascular event during the first year following randomization Have at least one follow-up visit following the first annual visit ALLHAT

Percent Remaining on Step 1 Monotherapy at Subsequent Annual Visits Step 1 DrugYear 2Year 3Year 4Year 5Yrs. 1-5 Chlorthalidone (n=7387) Amlodipine (n=4275) Lisinopril (n=3638) Doxazosin (n=3180) ALLHAT n=number in year 1 cohort

Cox Regression Analyses Baseline variables –Age, gender, race, ethnicity, SBP, DBP, previous antihypertensive med use, aspirin use –History of atherosclerotic CVD, coronary revascularization, diabetes, CHD, LVH, smoking –Serum potassium, creatinine, total & HDL cholesterol, fasting glucose and triglycerides Time-dependent variables –On/off Step 1 monotherapy, SBP, DBP, serum potassium, creatinine, total cholesterol –Variables updated annually –Missing value  values from previous year brought forward ALLHAT

Baseline Characteristics CALD No. randomized Age, yr, mean % women *46.2* Race, % White *62.2* Black Other ALLHAT *p<0.05; overall race distribution significantly different in lisinopril and doxazosin treatment groups compared to chlorthalidone group

Baseline Characteristics CALD Previous AHT RX, % BP, mm Hg, mean Treated143/83 142/83 Untreated155/89156/90155/89155/88 Prior CABG/PTCA, % *10.6 Taking aspirin, % *34.4* HDL-C, mg/dl, mean *46.6 Serum potassium, mmol/l, mean * *p<0.05 ALLHAT

Systolic Blood Pressure ALLHAT

Improvement in SBP from Baseline ALLHAT

Adjusted* Analyses for Major Cardiovascular Outcomes: Amlodipine vs. Chlorthalidone ALLHAT OutcomeHR95% CIP CHD (Primary) , Mortality , Combined CHD , Stroke , Combined CVD , 1.25<0.01 Heart failure (all) , 1.82<0.001 Heart failure (H+F) , 1.92<0.001 *Baseline-adjusted for age, gender, race, ethnicity, smoking status, BP, BP meds, LVH, aspirin use, fasting glucose, creatinine, total cholesterol, HDL cholesterol, potassium; history of ASCVD, diabetes, CHD, coronary revascularization

Adjusted* Analyses for Major Cardiovascular Outcomes: Lisinopril vs. Chlorthalidone OutcomeHR95% CIP CHD (Primary) , Mortality , Combined CHD , Stroke , Combined CVD , Heart failure (all) , Heart failure (H+F) , ALLHAT *Baseline-adjusted for age, gender, race, ethnicity, smoking status, BP, BP meds, LVH, aspirin use, fasting glucose, creatinine, total cholesterol, HDL cholesterol, potassium; history of ASCVD, diabetes, CHD, coronary revascularization

Adjusted* Analyses for Major Cardiovascular Outcomes: Doxazosin vs. Chlorthalidone OutcomeHR95% CIP CHD (Primary) , Mortality , Combined CHD , Stroke , Combined CVD , Heart failure (all) , 2.26<0.001 Heart failure (H+F) , 2.37<0.001 ALLHAT *Baseline-adjusted for age, gender, race, ethnicity, smoking status, BP, BP meds, LVH, aspirin use, fasting glucose, creatinine, total cholesterol, HDL cholesterol, potassium; history of ASCVD, diabetes, CHD, coronary revascularization

Heart Failure in ALLHAT ALLHAT * * * * * * * * * *P<0.05 † Time-dependent analyses adjusted for the following time-dependent variables: SBP, DBP, on/off treatment, and serum potassium, creatinine, and cholesterol. Also adjusted for baseline variables: age, gender, ethnicity, BP, LVH, smoker, aspirin use, BP meds at baseline; history of atherosclerotic cardiovascular disease, coronary revascularization, diabetes, CHD. †

Stroke in ALLHAT ALLHAT *P<0.05 * * † Time-dependent analyses adjusted for the following time-dependent variables: SBP, DBP, on/off treatment, and serum potassium, creatinine, and cholesterol. Also adjusted for baseline variables: age, gender, ethnicity, BP, LVH, smoker, aspirin use, BP meds at baseline; history of atherosclerotic cardiovascular disease, coronary revascularization, diabetes, CHD. †

Stroke in ALLHAT: Black Participants ALLHAT *P<0.05 * * † Time-dependent analyses adjusted for the following time-dependent variables: SBP, DBP, on/off treatment, and serum potassium, creatinine, and cholesterol. Also adjusted for baseline variables: age, gender, ethnicity, BP, LVH, smoker, aspirin use, BP meds at baseline; history of atherosclerotic cardiovascular disease, coronary revascularization, diabetes, CHD. † *

Conclusions (1) Heart failure, increased in the assigned (intent-to-treat) Step 1 amlodipine and doxazosin treatment groups compared to the chlorthalidone group, is similarly increased in these treatment groups in this Step 1 monotherapy cohort. ALLHAT

Conclusions (2) The previously reported higher rates for stroke and CCVD, including heart failure, in the lisinopril group compared to the chlorthalidone group, do not reach significance in this monotherapy cohort. –The restricted cohort lessens the sample size. –BP differences are greatly diminished with this restricted cohort. –Participants with early CVD events are not included. ALLHAT

Conclusions (3) Unknown confounding factors may further influence results, and thus caution in interpretation is warranted. ALLHAT

Alternate Slides

Heart Failure in ALLHAT Relative Risk A vs CL vs CD vs C ALLHAT population (ITT)1.38*1.19*1.80* Year 1 monother. cohort: Unadjusted 1.39* * Year 1 monother. cohort: Baseline-adjusted 1.49* * Year 1 monother. cohort: Time-dependent † 1.43* * ALLHAT † Time-dependent variables: SBP, DBP, on/off treatment, and serum potassium, creatinine, and cholesterol; also adjusted for baseline variables * P < 0.05

Stroke in ALLHAT Relative Risk A vs CL vs CD vs C ALLHAT population (ITT) *1.26* Year 1 monother. cohort: Unadjusted Year 1 monother. cohort: Baseline-adjusted Year 1 monother. cohort: Time-dependent † ALLHAT † Time-dependent variables: SBP, DBP, on/off treatment, and serum potassium, creatinine, and cholesterol; also adjusted for baseline variables * P < 0.05

Stroke in ALLHAT: Black Participants Relative Risk A vs CL vs CD vs C ALLHAT Black population (ITT) *1.38* Year 1 monother. cohort: Unadjusted Year 1 monother. cohort: Baseline-adjusted Year 1 monother. cohort: Time-dependent † * ALLHAT † Time-dependent variables: SBP, DBP, on/off treatment, and serum potassium, creatinine, and cholesterol; also adjusted for baseline variables * P < 0.05